Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Donepezil is a small molecule pharmaceutical drug classified as a cholinesterase inhibitor. It is primarily used to treat dementia associated with Alzheimer's disease, including mild, moderate, and severe stages. Donepezil works by reversibly inhibiting acetylcholinesterase in the brain, thereby increasing acetylcholine concentrations at cholinergic synapses and improving cognitive function such as memory and attention. In addition to its main mechanism of action on acetylcholinesterase, donepezil also acts as an agonist of the sigma-1 receptor and may upregulate nicotinic receptors in cortical neurons. While it can improve symptoms or slow their progression in Alzheimer's disease patients, it does not cure the underlying condition or halt its eventual progression[1][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on donepezil.